As shares of Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX have rallied following a press release concerning phase 3 studies of its Lumacaftor Ivacaftor combination regime, Bernstein analyst Geoffrey Porges issued a note with his take on the stock.
Despite today's move, Porges maintained his Market-perform rating and $65 price target.
Porges noted the data are "clearly better than expected" but believes the immediate potential of the combination is substantially priced in. Moreover, he thinks short-covering will initially exaggerate the move.
Looking forward, Porges expects the regimen to receive FDA approval.
For a more detailed look into the press release read
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in